Factors for recurrence in acute central serous chorioretinopathy patients underwent one-third dose verteporfin photodynamic therapy

•We aim to investigate the factors of recurrence in acute central serous chorioretinopathy(aCSC) patients underwent one-third dose verteporfin photodynamic therapy(PDT),though it is an uncommon therapy for aCSC which also showed satisfying efficacy in our study.•We found that recurrence is associated with retinal pigment epithelium(RPE) damage, baseline best-corrected visual acuity(BCVA) and subfoveal choroidal thickness(SCT) level,and our findings will assist clinicians to evaluate aCSC in clinical practice and provide insights into the prevention of recurrence.•The worldwide shortage of verteporfin also has enormous clinical impact on ophthalmic care which also makes our study more valuable. To investigate the factors for recurrence in acute central serous chorioretinopathy (aCSC) for patients who underwent one-third dose verteporfin photodynamic therapy (PDT). A retrospective study was performed in aCSC patients treated with one-third dose PDT and followed up for 36 months. Demographic information and clinical features were compared. A logistic regression model was used to evaluate the associated factor of aCSC recurrence. There were 162 patients with aCSC included in current study. 36-month after one-third dose PDT, good recovery was identified in 131 patients (80.86%), whereas 31 cases (19.14%) developed recurrence. Significant between-group differences were observed in baseline age, the right, left and both eyes, best-corrected visual acuity (BCVA), presenting with pigment epithelium detachment (PED), retinal pigment epithelium (RPE) damage and subfoveal choroidal thickness (SCT) level (P = 0.005, P